As of November 9, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Alvotech. The largest reported stake is Aztiq Pharma Partners S.a r.l.'s, at 33.3%. 2 filings are on record since March 12, 2026 (Schedule 13D/A, March 12, 2026).
Sell to companies like Alvotech? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Alvotech has 2 Schedule 13D or 13G filings on record since 2026-03-12. 2 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Aztiq Pharma Partners S.a r.l. | 33.3% | 103,849,420 | SCHEDULE 13D/A, 2026-03-12 | 2025-12-17 |
| Celtic Holdings S.C.A. | 27.5% | 107,450,988 | SCHEDULE 13D/A, 2026-06-30 | 2026-06-26 |
Holding shares or following this stake? See who's behind Alvotech and the warning signs.
Free to see. No signup.
Watch Alvotech
Get an email when Alvotech files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alvotech?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Alvotech: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alvotech covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Celtic Holdings S.C.A. | 0 | 107,450,988 | 0 | 107,450,988 | SCHEDULE 13D/A, 2026-06-30 |
| Celtic Lux Holdings S.a r.l. | 0 | 107,450,988 | 0 | 107,450,988 | SCHEDULE 13D/A, 2026-06-30 |
The latest filing identifies Alvotech by CUSIP L01800108 and gives its principal executive office as 9, Rue de Bitbourg, Grand Duchy of Luxembourg (SCHEDULE 13D/A, 2026-06-30).
Source of funds (Item 3)
Item 3 is hereby amended and supplemented as follows: The Ordinary Shares acquired in the PIPE Investment (as defined in Item 4 below) were funded through the proceeds of the Loan (as defined in Item 6 below).Celtic Holdings S.C.A., SCHEDULE 13D/A, 2026-06-30
Purpose of Transaction (Item 4)
Celtic Holdings S.C.A.
Item 4 is hereby amended and supplemented as follows: On June 26, 2026, Celtic Lux purchased aggregate of 10,133,333 Ordinary Shares, at a price of $3.75 per share, for an aggregate investment of $38,000,000 (such investment, the "PIPE Investment") pursuant to the terms of a subscription agreement (the "Subscription Agreement") dated June 16, 2026, by and between Celtic Lux and the Issuer. In connection with the PIPE Investment, pursuant to the Subscription Agreement, Celtic Lux was granted registration rights pursuant to which Celtic Lux may, at any time and from time to time, make a written demand for registration under the Securities Act of 1933, as amended, of all or any portion of the shares purchased by it in the PIPE Investment on any available form of registration statement (a "Demand Registration"), including by way of an underwritten offering with underwriters selected by Celtic Lux and reasonably acceptable to the Issuer. The Issuer is obligated, using its reasonable best efforts and as expeditiously as possible after receipt of such demand, to prepare and file with the SEC a registration statement covering the resale of such shares and to keep such registration statement effective until all such shares have been disposed of or withdrawn. The Issuer is not obligated to effect more than two (2) Demand Registrations in total. The Issuer has the right to defer any Demand Registration for up to 60 days in total, or 30 consecutive days, in any 12-month period if the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-30; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-12 | Aztiq Pharma Partners S.a r.l. | 33.3% | SCHEDULE 13D/A |
| 2026-06-30 | Celtic Holdings S.C.A. | 27.5% | SCHEDULE 13D/A |
Questions about who owns Alvotech
Who owns Alvotech?
On this page, 2 holders' latest ownership filings report 5% or more of Alvotech: Aztiq Pharma Partners S.a r.l. (33.3%, Schedule 13D/A, filed 2026-03-12) and Celtic Holdings S.C.A. (27.5%, Schedule 13D/A, filed 2026-06-30).
Who are the largest shareholders of Alvotech?
By the share each holder's latest filing reports, the largest holders of Alvotech on this page are Aztiq Pharma Partners S.a r.l. (33.3%) and Celtic Holdings S.C.A. (27.5%).
When did Aztiq Pharma Partners S.a r.l. buy into Alvotech?
The filings give report dates, not purchase dates. The earliest filing from Aztiq Pharma Partners S.a r.l. on this page is the Schedule 13D/A, filed 2026-03-12, reporting 33.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Alvotech. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.